DAXOR CORPORATION

(DXR)
  Rapport
Vertraagde tijd Nyse  -  20:50 08-08-2022
13.90 USD   +1.02%
21/07Daxor Corporation kondigt partnerschap met Medaxiom aan
CI
27/06Daxor en de Uniformed Services University gaan samenwerken aan een nieuw apparaat voor de analyse van het bloedvolume
MT
27/06Daxor Corporation kondigt fase II-overeenkomst voor coöperatief onderzoek en ontwikkeling aan met de Uniformed Armed Services University voor de ontwikkeling van een niet-nucleair bloedvolume-analyseapparaat (Bva)
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société DAXOR CORPORATION
27/07Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Ove..
GL
27/07Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Ove..
AQ
21/07Daxor corporation announces partnership with medaxiom to advance awareness and further ..
GL
21/07Daxor corporation announces partnership with medaxiom to advance awareness and further ..
AQ
18/07Daxor completes nih funded i-corps program for commercialization of clinical decision s..
GL
18/07Daxor completes nih funded i-corps program for commercialization of clinical decision s..
AQ
29/06DAXOR CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
27/06Daxor announces cooperative research and development phase ii agreement with the unifor..
GL
27/06Daxor announces cooperative research and development phase ii agreement with the unifor..
AQ
13/06Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Asso..
GL
13/06Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Asso..
AQ
25/05Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “..
GL
25/05Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “..
AQ
12/05Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Confere..
GL
12/05Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Confere..
GL
02/05New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients wit..
GL
02/05New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients wit..
AQ
06/04New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor's Blood..
AQ
23/03Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
AQ
01/03Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Lett..
AQ
01/03Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fi..
AQ
17/02Study Demonstrates Importance and Clinical Utility of Daxor's Blood Volume (BVA-100®) D..
AQ
02/02DAXOR : Commences Trading on The NASDAQ Capital Market - Form 8-K
PU
02/02DAXOR CORP : Other Events (form 8-K)
AQ
02/02Daxor Corporation Commences Trading on The NASDAQ Capital Market
AQ
24/01DAXOR CORP : Change in Directors or Principal Officers (form 8-K)
AQ
21/01Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors
GL
20/01DAXOR : to Commence Trading on The Nasdaq Capital Market On February 2, 2022 - Form 8-K
PU
20/01DAXOR CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar..
AQ
20/01Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022
AQ
06/01Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
AQ
05/01Daxor announces key milestones achieved for multicenter bva-100® study in hospitalized ..
AQ
04/01Daxor awarded new patent for blood volume guidance technology to improve treatment and ..
AQ
2021Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test f..
AQ
2021New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®)..
AQ
2021DAXOR CORPORATION : Receives $200K Matching Fund Award from Launch Tennessee
AQ
2021Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test f..
GL
2021DAXOR CORPORATION : To Present Compelling New Data and Clinical Trials Utilizing the BVA-1..
AQ
2021DAXOR CORPORATION : to Present at the H.C. Wainwright 23rd Annual Global Investment Virtua..
AQ
2021DAXOR CORPORATION : CEO and President Michael Feldschuh Provides Corporate Update in Lette..
AQ
2021DAXOR CORPORATION : Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR ..
AQ
2021DAXOR : Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill..
AQ
2021DAXOR : Announces non-government distribution agreement with concordance® healthcare solut..
AQ
2021DAXOR : American College of Cardiology (ACC) Features Expert Analysis on the Importance of..
AQ
2021DAXOR CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021DAXOR : to Present at the Summer Solstice – Best Ideas from the Buy Side Conference ..
PU
2021Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conf..
GL
2021DAXOR CORPORATION : Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitio..
AQ
2021DAXOR CORP : Other Events (form 8-K)
AQ
2021DAXOR CORPORATION : Receives National Institutes of Health (NIH) Funding Notification for ..
AQ
2021DAXOR : Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-1..
AQ
2021Daxor corporation to participate in benzinga biotech small cap conference
GL
2021Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference
GL
2021DAXOR CORP : Other Events (form 8-K)
AQ
2021Daxor corporation announces novel fluorescent tracer and phase-two us air force contrac..
GL
2021Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
GL
2021Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fi..
GL
2021Daxor corporation receives iso 13485 quality management system certification for the bl..
GL
2021Daxor corporation awarded grant from the center for advancing point of care technologie..
GL
2021New Research Demonstrates the Clinical Utility with Daxor's Blood Volume Analyzer (BVA-..
GL
2021DAXOR : To exhibit at the society for critical care medicine 50th congress virtual event
AQ
2021DAXOR : Announces new distribution agreement with l1 enterprises government distributor
AQ
2021Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
GL
2020Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer ..
GL
2020DAXOR CORPORATION : to Present at the 13th Annual LD Micro Main Event 2020
AQ
2020DAXOR : Third hospital joins multicenter covid-19 bva-100® blood test study
AQ
2020Third hospital joins multicenter covid-19 bva-100® blood test study
GL
2020DAXOR : Oregon health & science university joins multicenter covid-19 bva-100® study
AQ
2020Oregon health & science university joins multicenter covid-19 bva-100® study
GL
2020DAXOR : to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
AQ
2020Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
GL
2020DAXOR : New Research Shows Daxor's BVA-100® Blood Test Provides Unique Benefit in Detectin..
AQ
2020New Research Shows Daxor's BVA-100® Blood Test Provides Unique Benefit in Detecting Ane..
GL
2020DAXOR CORP : Other Events (form 8-K)
AQ
2020DAXOR : New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost..
AQ
1  2  3  4Volgende